These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21191396)

  • 1. Patients' preference in the treatment of erectile dysfunction: a critical review of the literature.
    Morales AM; Casillas M; Turbi C
    Int J Impot Res; 2011; 23(1):1-8. PubMed ID: 21191396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
    Lee J; Pommerville P; Brock G; Gagnon R; Mehta P; Krisdaphongs M; Chan M; Chan J; Dickson R
    BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ED patients and their female partners prefer tadalafil].
    Gong BS
    Zhonghua Nan Ke Xue; 2011 Jun; 17(6):571-5. PubMed ID: 21735661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
    Wright PJ
    Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
    Zhang SX; Gao P
    Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
    Mulhall JP; Montorsi F
    Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
    Ahn TY; Lee SW; Kim SW; Yang DY; Park NC; Min KS; Park K; Paick JS; Dyachkova Y; Dwight T; Lee MS
    Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.
    Brock G; Chan J; Carrier S; Chan M; Salgado L; Klein AH; Lang C; Horner R; Gutkin S; Dickson R
    BJU Int; 2007 Feb; 99(2):376-82. PubMed ID: 17155989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.
    von Keitz A; Rajfer J; Segal S; Murphy A; Denne J; Costigan T; Lockhart D; Beasley CM; Emmick JT
    Eur Urol; 2004 Apr; 45(4):499-507; discussion 507-9. PubMed ID: 15041116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and treatment satisfaction in patients with erectile dysfunction in Spain: EDOS study].
    Martín-Morales A; Gutiérrez Hernández PR; Meijide Rico F; Arrondo Arrondo JL; Turbí Disla C
    Actas Urol Esp; 2010 Apr; 34(4):356-64. PubMed ID: 20470698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tadalafil and patients preference in the treatment of erectile dysfunction].
    Hu JL; Chen B
    Zhonghua Nan Ke Xue; 2006 Dec; 12(12):1145-8. PubMed ID: 17201266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
    Mirone V; Fusco F; Rossi A; Sicuteri R; Montorsi F
    BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men.
    Lee M
    Clin Ther; 2011 Nov; 33(11):1590-608. PubMed ID: 22036514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.